Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Nov-Dec;23(6C):4721-7.

Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer

Takamune Shibaji  1 , Mitsuo Nagao, Naoya Ikeda, Hiromichi Kanehiro, Michiyoshi Hisanaga, Saiho Ko, Akihisa Fukumoto, Yoshiyuki Nakajima
Affiliations
  • PMID: 14981919

Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer

Takamune Shibaji et al. Anticancer Res. 2003 Nov-Dec.

Abstract

Background: Hypoxia inducible factor-1 alpha (HIF-1 alpha) has been correlated with unfavorable prognosis in several cancers. The aim of this study was to investigate the impact of HIF-1 alpha expression on clinicopathological factors and to clarify whether or not HIF-1 alpha is correlated with angiogenesis and mutation of p53 in pancreatic cancer.

Materials and methods: Using immunohistochemical methods, we examined the expression of HIF-1 alpha, vascular endothelial growth factor (VEGF), p53 and intratumoral microvessel density (IMD) in 55 cases of primary pancreatic cancer.

Results: Immunohistochemical studies showed that 40.0% cases were positive and the status of HIF-1 alpha was significantly correlated with metastatic status (p = 0.048), VEGF expression (p = 0.026) and IMD (p = 0.0061). HIF-1 alpha is significantly related to prognosis in pancreatic cancer.

Conclusion: Our data demonstrate that pancreatic cancer widely expresses HIF-1 alpha, which contributes to angiogenesis and progression. Therefore, assessment of HIF-1 alpha expression might be useful for predicting the prognosis of pancreatic cancer patients.

PubMed Disclaimer

Publication types

Substances